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a village but smaller than a city located in Berry, south of the Loire
Valley. This was – and still is – a region of agriculture with some
renowned products such as welsh rabbits, goat cheeses, and white
asparagus. It was the place where my mother had grown up but, in
fact, I never lived there.
Onmy father's side, his parents came from Auvergne, a province of
the center of France, made of rich plains and older volcanoes, the later
probably being at the origin of my family name: Montagnier, the man
living in mountains.
My father had in his youth caught a terrible disease: streptococcus
linked arthritis, ending in irreversible lesions in the aortic valve.
Therefore, he was declared unﬁt for military service and had to ﬁnd a
sedentary job: he became an accountant, and excelled in this
profession which implied, at that time, mainly handwritten work.
He started working in the Poitiers area, and thenmoved a little farther
north in Chatellerault, a small city between Tours and Poitiers.
As an only child, I was cherished bymymother, a housewife, but two
events dominated this “pre-war”period, ofwhich I keep avividmemory:
I was badly hit by a high speed running car when crossing a main
road: multiple wounds of which I keep some visible scarves, 2 days in
coma, but I emerged from it as if I was born again, at the age of 5 (Fig. 1).
…and 2 years later came the declaration of war in 1939, while all
the family was harvesting grapes in the vineyards of my mother's
brother. I still remember the images in a newspaper of Warsaw ruins
after a bombing by German planes.
And then, in 1940, came the German invasion: my parents and I
leaving our house (close to a risky railway station), ﬂeeing on the
roads in a little car, and ﬁnally more exposed to German bombing
during this exodus than if we had stayed home.
The ﬁrst year of German occupation was terrible, in that we had no
food reserves and most of the time, we were starving. I was a rather
puny boy and during the 4 years of the war, did not gain a gram! The
food substitutes (ersatz) did not stimulate my appetite, when I was
dreaming of chocolate and oranges! My father had chronic entero-
colitis and, worst, my grandfather (his father) was diagnosed with
rectal cancer. He died in 1947 after terrible suffering and each time I
visited him, I could see the inexorable progression of the disease. This
affected me so much that it is probably one reason why I decided later
to study medicine and to start research on cancer.
In June 1944, our house (so close to the railway) was partly
destroyed this time by an allied bombing. I keepmixed feelings of this
year of liberation of France. It was a great relief, but I also cannot
forget the vision of so many killed people, civilians and soldiers, and☆ This manuscript covers the contents of the Nobel Lecture presented at the
Karolinska Institute, Stockholm, Sweden on December 7, 2008, and it is reprinted with
the permission of The Vobel Foundation.
doi:10.1016/j.virol.2009.11.004the images of skinny deportees released from concentration camps. I
have hated wars and their atrocities for the rest of my life.
At high school, I was doing well, being usually ahead of my class
mates. This is the time at which I became curious of the scientiﬁc
knowledge, having left behind my religious catholic belief.
Following the example of my father who was tinkering in his
leisure days with electric batteries, I set up a chemistry laboratory in
the cellar of the new house which was requisitioned to accommodate
us. There, I enthusiastically produced hydrogen gas, sweet-smelling
aldehydes and nitro compounds (not nitro-glycerine!) that had the
unfortunate habit of blowing up in my face.
I was delighted to read – in popularized books – the impressive
progress of physics – especially atomic physics. Being good in physics
and chemistry – but not as good in maths – I decided not to prepare
for the competitions for the “Grandes Ecoles” but instead to register
both at the School of Medicine and the Faculty of Sciences of Poitiers.
My goal was in fact to start a research carrier in human biology but
there was no such specialty in Poitiers, neither in Medicine, nor in
Sciences. Since both Faculty and School were at walking distance, I
could spend the morning at the hospital and the afternoon attending
courses in botany, zoology and geology which were the main
disciplines of the License of Sciences.
Fortunately, the new Professor of Botany, Pierre Gavaudan, was a
very atypical professor in that his scientiﬁc interests were going far
beyond the classiﬁcation of plants. In fact, I owe him to have openedme
a large window on what was the beginning of a new Biology, the DNA
double helix, the in vitro synthesis of proteins, the structure of viruses.
At the same time, I installed in my home a microscope with a
time-lapse movie camera, thanks to a gift of my father. This allowed
me to do my ﬁrst research work. I was studying a phenomenon
known since 1908 as the phototaxy of chloroplasts: the property of
some algae living at the surface of ponds to orient their large
unique chloroplast according to the intensity of light; if the light
was too intense, the chloroplast turned inside the tubular cell to
present its edge. In dark or weaker light, the chloroplast, a ﬂat plate,
exposed its larger surface. The phenomenon took a few minutes,
which could be analyzed by time-lapse cinematography. Using
different glass ﬁlters, I could show that it was not the wavelength
absorbed by the chlorophyll (red light) which could regulate the
orientation of the chloroplasts but indirectly some yellowish
pigments absorbing the blue light. I was very proud, at the age of
21, to present this work as a small thesis at the Faculty of Sciences
of Poitiers. I was asked by my mentor, Pierre Gavaudan, to write a
dissertation also on a literature based subject: it was the L-forms of
bacteria. This allowed me to do my ﬁrst incursion – not the last – in
the world of ﬁltering bacteria. I could only ﬁnd the references on
this controversial subject at the library of the Pasteur Institute in
Paris. This was indeed the time at which I left Poitiers to Paris,
Fig. 2.
Fig. 1.
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aspects of biology closer to human beings, particularly neuro
physiology, virology and oncology.
Having been hired as an assistant at the Sorbonne at the age of 23, I
started learning old-fashioned technologies derived from the work of
Alexis Carrel on chick embryo heart cultures, as well as that of human
cell lines in monolayers. Although my research was not productive at
all, I learned from this period a solid expertise of Pasteurian
technologies for working in perfectly sterile conditions, without the
use of antibiotics.
In 1957, the ﬁrst description of infectious viral RNA from the
Tobacco Mosaic Virus by Fraenkel-Conrat and Gierer and Schramm,
determined my vocation: to become a virologist using the modern
approach of molecular biology.
I started with the Foot and Mouth Virus in Kingsley Sanders'
laboratory at Carshalton near London. Kingsley was an atypical
British man, a writer of opera music in his leisure days. He gave me
the entire freedom to choose an approach for elucidating the
replication of small RNA viruses. I was proud to identify for the ﬁrst
time an infectious double-stranded RNA from cells infected with the
murine Encephalomyocarditis Virus, a small single-stranded RNA
virus. This demonstrated for the ﬁrst time that RNA can replicate like
DNA, by making a base-paired complementary strand.
In order to complete my knowledge of oncogenic viruses, I
moved from Carshalton to Glasgow where a new Institute of
Virology had been recently inaugurated, headed by a remarkable
virologist, Michael Stocker, and where many high ranking visitors,
among them, Renato Dulbecco, were spending sabbatical years.
Working on a small oncogenic DNA virus, polyoma, I could show
there, with Ian Macpherson, a new property of transformed cells, that
of growing in soft agar. Using this technique, it was easy to detect the
transforming capacity of polyoma virus and its DNA. We showed that
naked DNA alone carried all the oncogenic potential of the virus. This
looks now pretty obvious, but it was not so at that time.
Back to France at the Institute Curie, I extended this ﬁnding to a
number of cancer cells, transformed or not by oncogenic RNA or
DNA viruses. Moreover, this property allowed me to distinguish
some in vitro steps in the process of transformation which were
correlated with some modiﬁcations of the plasma membrane and of
the carbohydrate layer surrounding it.A great mystery remained at that time: that of the replication of
the oncogenic RNA viruses, now known as retroviruses. Howard
Temin (Fig. 2) had proposed the hypothesis of a DNA intermediate,
but other possibilities could be considered. I myself tried to ﬁnd a
double-stranded RNA speciﬁc of the Rous sarcoma virus, a virus able
to infect and transform chick embryo cells. I indeed isolated double-
stranded RNA sequences, but they were of cellular origin and existed
at the same level in non-infected cells! With Louise Harel, I showed
later that this RNA was partly coming from repetitious sequences of
DNA. In retrospect, it could, at least in part, represent the recently
identiﬁed interfering RNAs involved in the negative control of
messenger RNA translation.
In 1969–70, the isolation of an RNA-polymerase associated with
the viral particles of the vesicular stomatitis virus, led to the idea that
perhaps a key-enzyme was also associated with the oncogenic RNA
viruses. Indeed, Howard Temin and Mizutani, and independently
David Baltimore, discovered in 1970 a speciﬁc enzyme associatedwith
Rous sarcoma virus (RSV), the reverse transcriptase (RT), capable to
reversely transcribe the viral RNA into DNA.
At about the same time, Hill and Hillova in Villejuif, France,
demonstrated that the DNA extracted from RSV transformed cells was
infectious and carries the genetic information of the viral RNA,
conﬁrming that the enzyme was working faithfully in infected cells.
P. Vigier and I conﬁrmed and extended this discovery by showing
that the infectious DNA was associated with the chromosomal DNA of
the cells, showing integration of the proviral DNA, as earlier
postulated by Temin.
The work on the chicken RSV was extended to similar viruses of
mammals, so that many researchers at that time believed that the RT
activity was a new highly sensitive tool to detect similar viruses in
human leukemia and cancer. This was stimulated by the largely
funded virus-cancer program launched by the American NIH.
Unfortunately, the hunt for human retroviruses was basically
unsuccessful but led to important basic work on the molecular
biology of animal retroviruses and the discovery of oncogenes, the
“cancer genes”.
In 1972, Jacques Monod, then heading the Pasteur Institute,
proposed that I create a research Unit in the newly created
Department of Virology of the Institute. I accepted the offer and this
new laboratory allowed me to develop new avenues of research
within the general theme of Viral Oncology with the ultimate goal
remaining the detection of virus involved in human cancers.
Thus, I became interested in the mechanism of action of interferon
and its role in its expression of retroviruses. I came in this ﬁeld after
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RNA in collaboration with two world-known experts in the ﬁeld,
Edward and Jacqueline De Maeyer.
From 1973 and on, Ara Hovanessian and his co-workers joined my
Unit and added a new dimension on the subject: the complex
biochemical mechanism sustaining the antiviral activity of this
remarkable group of cellular proteins.
In 1975, two other researchers joined my Unit and brought their
expertise on murine retroviruses: it was Jean-Claude Chermann and
his collaborator, Françoise Barré-Sinoussi (Fig. 3). The latter had
mastered the detection of retroviruses by their RT activity. I convinced
them to participate in a joint study inside the Unit to look again for
retroviruses in human cancers. We started in 1977 with blood sam-
ples coming from different Parisian Hospitals and biopsy specimens.
Two advances made in other laboratories boosted this search:
In Villejuif, France, Ion Gresser had prepared a potent antiserum
neutralizing any molecule of alpha endogenous interferon produced
by individual cells. This interferon, we realized, was produced by
mouse cells induced to express some of their endogenous retro-
viruses. Its blockade by the antiserum increased by up to 50 times the
production of endogenous retroviruses in the culture medium. We
could conclude that, despite the fact that endogenous retroviruses are
integrated in the genome of vertebrates for millions of years, their
expression is still controlled by the interferon system, like that of
exogenous viruses!
At about the same period, the discovery by Doris Morgan and
Frank Ruscetti in Dr Gallo's laboratory of a growth factor allowing the
in vitro multiplication of human T lymphocytes (TCGF, then named
interleukin 2, IL-2) made it possible to propagate T lymphocytes in
sustained cultures.
We knew at that time that some retroviruses involved in mouse
mammary tumor formation (MMTV) could not only be expressed in
the tumor cells but also in the circulating lymphocytes.
Taking advantage of these two advances, we started a search for
retroviruses in human cancers, using anti-interferon serum and IL-2,
with particular focus on the T lymphocyte cultures from breast cancer
patients.
Indeed, in 1980, we were able to detect a DNA sequence close to
that MMTV not only in the cells of an inﬂammatory breast cancer
(from a North African woman), but also in her cultured T
lymphocytes. A second patient showed similar results.
Unfortunately, the molecular tools we had at that time could not
tell us whether we were dealing with endogenous retroviralFig. 3sequences or with an exogenous virus. Nowadays, having in hands
more powerful technologies, I am planning to reinitiate these studies.
But in 1983, the same approach, the use of anti-interferon serum,
and the use of long-term cultures of T lymphocytes greatly facilitated
the isolation of HIV.
My involvement in AIDS began in 1982, when the information
circulated that a transmissible agent – possibly a virus – could be at
the origin of this newmysterious disease. Therewere at that time only
a few cases in France, but they attracted the interest of a group of
young clinicians and immunologists. They were looking for virolo-
gists, especially retro-virologists, as a likely hypothesis was that HTLV
– the only human retrovirus known so far, recently described by R.C.
Gallo – could be involved. Retroviruses causing leukemia in rodents
often cause also a wasting syndrome which could be the result of
secondary immune depression. This was also the case of patients
suffering from leukemia induced by HTLV.
A member of the working group, Françoise Brun-Vézinet, was a
former student of the Virology Course I was then directing. She
called me up to organize the search of the putative retrovirus from
a patient presenting with an early sign of the disease, lymphodeno-
pathy. The patient was a young gay man who had been traveling to
the USA, who was consulting Dr. Willy Rozenbaum – one of the
leaders of the working group – for a swollen lymph node in the
neck. The gland was not painful; it was just for the patient a
question of aesthetics.
The reasoning was that if we were to ﬁnd a virus at this early stage
of the disease, it could be more a cause than a consequence of the
immune depression.
Another incentive to start this research was a request from the
producers of hepatitis B virus vaccine in the industrial subsidiary of
the Pasteur Institute. They were using plasma from American blood
donors and were concerned by the risk of transmission of the AIDS
agent through their procedure of viral antigen puriﬁcation.
The lymph node biopsy arrived on January 3, 1983, a date which I
remember well because it was also the ﬁrst day of the Virology Course
at the Pasteur Institute which I had to introduce. I could dissect the
small hard piece only at the end of the day. I dissociated the
lymphocytes with a Dounce glass homogenizer and started their
stimulation in culture with a bacterial mitogen, Protein A, known as
an activator of B and T lymphocytes, since I did not know which
fraction of lymphocytes could produce the putative virus. Three days
later, I added the T cell growth factor I had obtained from a colleague
working in the laboratory of Jean Dausset..
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the search of retrovirus in human cancers, it was decided with my
associates, Françoise Barre-Sinoussi and Jean-Claude Chermann, to
measure the RT activity in the culture medium every 3 days. In day 15,
Françoise showed me a hint of positivity (incorporation of radioactive
thymidine in polymeric DNA), which was conﬁrmed on the following
week.
We had evidence of a retrovirus, but this was just the beginning of
a series of questions:
Was it close to HTLV or not?
Was it a passenger virus or, on the contrary, the real cause of the
disease?
In order to answer these basic questions, we had to characterize
the virus biochemically and immunologicaly, and for that, we needed
to propagate it in sufﬁcient amounts. Fortunately, the virus could be
easily propagated in activated T lymphocytes from adult blood
donors. No cytopathic effect was observed with this ﬁrst isolate, but
unlike HTLV infected cultures, no transformed immortalized cell lines
could emerge from the cultures, which always died after 3–4 weeks as
do normal lymphocytes.
By contrast, subsequent isolates I made from culture of lympho-
cytes of sick patients with AIDS were cytopathic for T lymphocytes
culture and – we discovered later – could be grown up in larger
amounts in tumor cell lines derived from leukemia.
Shortly after the virus isolation, my co-workers and I could show
that it was not immunologicaly related to HTLV, and in electron
microscopy, it was very different from HTLV viral particles. In fact, as
soon as June 1983, I noticed the quasi identity of our virus with the
published electronmicroscopy pictures of the visna virus of sheep, the
infectious anemia virus of horse, the bovine lymphocytic virus: it was
a retrolentivirus, a subfamily of viruses causing in animals long lasting
disease without immunodeﬁciency.
This indicated clearly that we were dealing with a virus very
different from HTLV, and my task was now to organize a team of
researchers to accumulate proofs that this new virus was indeed the
cause of AIDS.
It was an exciting period since every Saturday morning, when we
had a meeting in my ofﬁce, new data were brought by my associates
favoring the causative role of the virus. The viral isolates were called
LAV, for Lymphadenopathy Associated Virus, when they were isolated
from patients displaying swollen lymph nodes, a frequent sign of the
early phase of infection. The isolates made from patients with full
blown AIDS were called Immuno Deﬁciency Associated Viruses
(IDAV). The latter generally grew better in T lymphocyte culture
and induced the formation of large syncitia, resulting from the fusion
between several infected cells. Some of them – we found it later –
could also multiply in continuous cell lines of B or T cell origin. The
later property greatly facilitated the massive production of the virus
for commercial use.
By September 1983, I could make a synthetic presentation of all
our data favoring a causal link between the virus and the disease at a
meeting on the HTLV organized by L. Gross and R. Gallo at Cold Spring
Harbor.
This presentation was received with skepticism by a scarce
audience (it was a late night session) and the HTLV theory was still
prevailing. Mentally, most attendants were not prepared to accept
the idea of a second family of retroviruses (lentiretroviruses)
existing in humans and causing immune deﬁciency, and having no
counterpart in animals!
This situation is not infrequent in science as new discoveries often
raised controversy. The only problem is that it was a matter of life and
death for blood transfused people and hemophiliacs, since a serologic
blood test using our virus antigens was already working at the
laboratory scale, but awaited industrial and commercial developments.This came in 1985, after two other teams of researchers – ﬁrst
that of Dr Gallo at NIH in early 1984 and that of Jay Levy in San
Francisco – conﬁrmed and extended our ﬁndings. In particular, Dr
Gallo and his associates gave more strength to the correlation
between the virus and the disease, improved the detection of the
antibody response and could grow several viral strains, including
ours, in T cell lines of cancer origin. Meanwhile, my co-workers
showed the tropism of the virus for CD4+ cells and identiﬁed the
CD4 surface molecule as the main receptor to the virus.
The rest of the story is described in the next chapter. I would just
like to illustrate how I discovered what I believe are two important
phenomena for explaining the destruction of the immune system
induced by HIV.
During the latent phase of the infection, no virus is found in the
blood, it is mostly localized in lymphocytes of lymphatic tissues and
yet, we found that most of the lymphocytes present in the blood are
sick! In 1987, a young visitor from Sweden, Jan Alberts, came to my
lab. He wanted to cultivate human lymphocytes in serum-free
synthetic medium and to learn some technologies about HIV culture.
The surprise came when we compared in his medium the viability of
lymphocytes from healthy donors and those from HIV infected
patients, even in their early-asymptomatic-stage of infection. While
the former could survive several days without dying, the majority
(more than 50%) of the latter died very quickly. Addition of
interleukin 2 partially prevented their death.
When we used normal culture medium supplemented with fetal
calf serum, the same difference was observed, although the survival
time of the lymphocytes from infected patients was longer.
It took not very long before three of my collaborators found the
reason of such deaths: apoptosis. This is an active process by which
the cell “decides” to die in a clean way, without releasing too much of
toxic compounds into the medium.
It is a physiological way to prevent abnormal proliferation of
activated lymphocytes clones, but here the phenomenon was
enormous and occurred not only on the main cellular targets of HIV
infection, CD4+ T lymphocytes, but also on cells which were not
infectable by the virus, such as CD8+ T lymphocytes, B-lymphocytes,
monocytes, natural killer cells…. Clearly, it was a general phenom-
enon, the culture simply revealing a predisposition to apoptosis of the
majority of circulating blood cells, although most of them were
neither infected nor infectable. Indeed, my collaborator, Marie-Lise
Gougeon, found a very good relation between in vitro apoptosis and
the in vivo observed drop of CD4 T cells in patients.
We have spent a lot of time trying to ﬁnd the origin of this massive
apoptosis, without ﬁnding a completely satisfactory explanation: the
most likely is the intensive oxidative stress existing in patients since
the beginning of their infection. This is also a ﬁnding I am very proud
of: although oxidative stress has been – and still is – completely
overlooked by AIDS researchers, it is likely to aggravate the wrong
activation of the immune system at the origin of its decline, and also to
trigger inﬂammation through the production of cytokines.
Of course, the next question arises: what are the factors causing
oxidative stress; viral proteins, fragments of viral DNA, co-infection
with mycoplasmas? Even after 25 years, we still do not know the
complete answer. But the phenomenon does exist and needs to be
treated, while most AIDS clinicians do not care of it at all!
The treatment by combined antiretroviral therapy has, without
doubt, changed the prognosis of this lethal disease, from death
condemnation to an almost “normal” life. However, the virus is still
there, ready tomultiply when the treatment is interrupted, and not all
HIV infected patients of the developing world have access to it! And
the epidemics still kill 2–3 millions of people each year. There is
therefore an absolute necessity to resolve these problems and basic
research, as well as clinical research, has to be continued.
In addition, I realized in the 1990s that research should not only be
localized in the wealthy laboratories of the developed countries, but
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AIDS and many other diseases like tuberculosis and malaria.
Too many examples showed that collaboration between North-
ern and Southern research laboratories is unequal, the South
providing serum samples to be analyzed in the North. This “safari”
concept is wrong. There are now many young researchers trained
in Northern laboratories who would like to come back to their own
countries, but are prevented to do so because laboratories and
adequate structures are missing. Moreover, one has to be on the
regions where disease proliferates to realize how complex is the
reality.
This is why I initiated with the former Director General of
UNESCO, Federico Mayor, a Foundation aimed at creating in African
countries Centres for Research and Prevention. Although the task
was difﬁcult, this concept met with enthusiastic colleagues and
medical doctors and also found the support of local governments,
particularly in Ivory Coast and Cameroun.I wish that from these pilot experiments, a whole network of
similar Centers could cover all the countries of the developing world
where the populations are badly hit by the epidemics.
Another lesson I drew from my AIDS experience was the
weakening effect of oxidative stress on the immune system and its
pro-inﬂammatory role in many chronic diseases, such as Parkinson,
Alzheimer, and rheumatoid arthritis; a likely consequence of chronic
infections? Or both consequence and cause? Many questions which
can be resolved only by hardwork and innovative thinking… I hope to
be able to continue both.
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